



ATTORNEY'S DOCKET NO. R0547/7007 (ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James K. Liao, et al.
Serial No. 09/273,445
Filed: March 19, 1999
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE
SYNTHASE BY HMG-COA REDUCTASE INHIBITORS
Examiner: Webman E. J.
Art Unit: 1617

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the 13th day of December, 2000.

Konstantinos Andrikopoulos
Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- ☒ Preliminary Amendment
- ☒ Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,

Edward R. Gates
Edward R. Gates, Reg. No.: 31,616
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Attorney's Docket No.: R0547/7007
Date: December 13, 2000
xNDD



ATTORNEY'S DOCKET NO. R0547/7007 (ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James K. Liao, et al.
Serial No. 09/273,445
Filed: March 19, 1999
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE
SYNTHASE BY HMG-COA REDUCTASE INHIBITORS
Examiner: Webman E. J.
Art Unit: 1617

DE 10/18

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the 13th day of December, 2000.

Konstantinos Andrikopoulos
Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the claims:

Please cancel claims ~~177-178, 183-184, 188-189, 197-198, 201-202, 207-212, and 213-214.~~

2 Please amend claims 179, 185, 190, 196, 199, 203, and 215, as follows: *2*

B1 179. (Amended) The method of claim [177] 167-174, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.

B2 185. (Amended) The method of claim [183] 181, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.

B3 190. (Amended) The method of claim [188] 187, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.